RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $18.17 Consensus PT from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has earned a consensus recommendation of “Hold” from the ten analysts that are presently covering the firm, Marketbeat.com reports. Nine investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $18.17.

Several research analysts have issued reports on the company. HC Wainwright reiterated a “neutral” rating on shares of RAPT Therapeutics in a report on Tuesday, August 20th. UBS Group cut their target price on RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a report on Monday, September 9th.

RAPT Therapeutics Stock Up 4.8 %

RAPT Therapeutics stock opened at $1.96 on Thursday. The company has a market capitalization of $68.40 million, a PE ratio of -0.64 and a beta of 0.33. RAPT Therapeutics has a 12-month low of $1.73 and a 12-month high of $27.35. The firm’s fifty day moving average is $2.33 and its 200 day moving average is $4.53.

RAPT Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.03. Sell-side analysts expect that RAPT Therapeutics will post -2.73 EPS for the current fiscal year.

Hedge Funds Weigh In On RAPT Therapeutics

Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of RAPT Therapeutics by 21.2% during the 1st quarter. Vanguard Group Inc. now owns 2,492,850 shares of the company’s stock worth $22,386,000 after purchasing an additional 436,629 shares during the period. Perceptive Advisors LLC grew its position in shares of RAPT Therapeutics by 11.4% during the 4th quarter. Perceptive Advisors LLC now owns 2,139,950 shares of the company’s stock valued at $53,178,000 after acquiring an additional 219,292 shares during the period. Kingdon Capital Management L.L.C. increased its stake in shares of RAPT Therapeutics by 55.3% during the 1st quarter. Kingdon Capital Management L.L.C. now owns 1,500,000 shares of the company’s stock worth $13,470,000 after purchasing an additional 534,172 shares during the last quarter. Federated Hermes Inc. raised its holdings in shares of RAPT Therapeutics by 188.7% in the 2nd quarter. Federated Hermes Inc. now owns 796,080 shares of the company’s stock worth $2,428,000 after purchasing an additional 520,368 shares during the period. Finally, Point72 Asset Management L.P. raised its stake in shares of RAPT Therapeutics by 176,725.0% in the second quarter. Point72 Asset Management L.P. now owns 707,300 shares of the company’s stock valued at $2,157,000 after buying an additional 706,900 shares during the period. Institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.